Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023GlobeNewsWire • 3h
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical TrialGlobeNewsWire • 03/16/23
Journey Medical Corporation to Participate in the 35th Annual ROTH ConferenceGlobeNewsWire • 03/07/23
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRGlobeNewsWire • 02/16/23
Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with TriplexGlobeNewsWire • 02/15/23
Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 02/10/23
Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 02/08/23
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)Accesswire • 01/31/23
Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial OfficerGlobeNewsWire • 01/20/23
Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular RosaceaGlobeNewsWire • 01/10/23
Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29GlobeNewsWire • 12/20/22
Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North AfricaGlobeNewsWire • 12/14/22
Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic ConferenceGlobeNewsWire • 12/06/22
Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic ConferenceGlobeNewsWire • 12/05/22
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/14/22
Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/14/22
Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/10/22
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022GlobeNewsWire • 11/03/22
Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred StockGlobeNewsWire • 10/05/22
Journey Medical Corporation to Participate in Upcoming October 2022 Investor ConferencesGlobeNewsWire • 10/04/22
Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/08/22